https://www.pharmaradar360.com/article/ce8456846a2ff1f3PharmaRadar360en2026-04-19T06:14:12.000ZPFA Under Deep Sedation and Non‐Invasive Monitoring in Atrial Fibrillation Patients With Obstructive Sleep Apneahttps://www.pharmaradar360.com/article/8090e7a59c5579dfPharmaRadar360en2026-04-19T06:10:14.000ZMultipoint Pacing Versus Cardiac Resynchronization Therapy in Heart Failure: A Systematic Review and Meta‐Analysishttps://www.pharmaradar360.com/article/0c98088ffca04367PharmaRadar360en2026-04-19T06:03:48.000ZAtrial Reverse Remodeling by Bachmann's Bundle Pacing With Improved Interatrial Dyssynchrony: Case Serieshttps://www.pharmaradar360.com/article/3725f296215d1353PharmaRadar360en2026-04-19T05:59:53.000ZStrength‐Duration Characterisation of Subcutaneous Pacing: A Preclinical Studyhttps://www.pharmaradar360.com/article/393f900566cc70d1PharmaRadar360en2026-04-19T03:45:14.000ZScientists say this type of olive oil could boost brain powerhttps://www.pharmaradar360.com/article/079c310c7c4f9dc6PharmaRadar360en2026-04-19T03:04:33.000Z10x Genomics Unveils Atera Spatial Platform at AACR Meetinghttps://www.pharmaradar360.com/article/e9c0ad7c3b91f7eaPharmaRadar360en2026-04-19T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/27a14b34a9a5974ePharmaRadar360en2026-04-19T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/b4006405bc0a21aaPharmaRadar360en2026-04-19T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/f16f2bcfeb7531cePharmaRadar360en2026-04-19T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/f0e59d5cce475f24PharmaRadar360en2026-04-19T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/eb1e157ea9908edcPharmaRadar360en2026-04-19T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/07f2c5e14da41332PharmaRadar360en2026-04-19T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/c5860d2357c2154ePharmaRadar360en2026-04-19T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/c2d3667800217c46PharmaRadar360en2026-04-19T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/a0aa201cd9077123PharmaRadar360en2026-04-19T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/c72803ab614b86d4PharmaRadar360en2026-04-19T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/7459a66d910cdda8PharmaRadar360en2026-04-19T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/d8265e329e099bdePharmaRadar360en2026-04-19T00:00:00.000Z6203https://www.pharmaradar360.com/article/3fb210180c683c7fPharmaRadar360en2026-04-19T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/b97e70d4c4684c90PharmaRadar360en2026-04-18T23:13:44.000ZThree gene therapy pioneers just won the Breakthrough Prize. This is their storyhttps://www.pharmaradar360.com/article/a075b48f50136515PharmaRadar360en2026-04-18T20:30:00.000ZZelicapavir Demonstrates High Clinical and Functional Barrier Against Antiviral Resistance: Results from a Randomized Double-Blind Placebo-Controlled Pediatric RSV Antiviral Clinical Trialhttps://www.pharmaradar360.com/article/292f40a55c3fcbdaPharmaRadar360en2026-04-18T20:29:00.000ZZelicapavir Decreases Symptom Duration, Hospitalization and Viral Load in a Global, Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of High-Risk Adults with RSVhttps://www.pharmaradar360.com/article/0294d9e731c9c3fdPharmaRadar360en2026-04-18T16:29:00.000ZPotent STAT6 Inhibitor EPS-3903 Has Excellent Preclinical Pharmacokinetics Enabling Sustained STAT6 Inhibition with Once-Daily Oral Dosing in Humanshttps://www.pharmaradar360.com/article/da6d995376702ffcPharmaRadar360en2026-04-18T14:08:55.000ZIt doesn’t matter how much you sit — walking more could lower your risk of death and diseasehttps://www.pharmaradar360.com/article/0a4c993a8c315e0cPharmaRadar360en2026-04-18T13:48:37.000ZUFRJ reúne professores eméritos em articulação permanente por ideias e soluções para a universidadehttps://www.pharmaradar360.com/article/6ba122f96e0e47d7PharmaRadar360en2026-04-18T13:05:40.000ZLive Updates From the AACR Annual Meeting 2026: Saturday, April 18https://www.pharmaradar360.com/article/c65a776f458dcef8PharmaRadar360en2026-04-18T10:00:24.000ZRevMed’s stunning success; FDA to reclassify peptides; and morehttps://www.pharmaradar360.com/article/689dc2fdedbc1cfaPharmaRadar360en2026-04-18T08:34:06.000ZOur Research Group at the PBP World Meeting 2026https://www.pharmaradar360.com/article/f0faa58cb542074cPharmaRadar360en2026-04-18T07:32:36.000ZArtificial neurons successfully communicate with living brain cellshttps://www.pharmaradar360.com/article/c7744c44b1319105PharmaRadar360en2026-04-18T07:30:00.000ZSevere malaria may affect children’s cognitive abilities more than a decade laterhttps://www.pharmaradar360.com/article/cc52e31ee9330290PharmaRadar360en2026-04-18T03:27:27.000ZEating more fruits and vegetables tied to unexpected lung cancer riskhttps://www.pharmaradar360.com/article/fad5a2fb946af86dPharmaRadar360en2026-04-18T00:00:00.000ZTherapeutic vulnerabilities exposed by the 9p21 loss identified through multiparametric drug screening inform rational combination strategieshttps://www.pharmaradar360.com/article/092e53e8d9dd53b1PharmaRadar360en2026-04-18T00:00:00.000ZSingle-cell transcriptomic landscape highlights epithelial-fibroblast interactions and CD44-mediated malignant traits in laryngeal squamous cell carcinomahttps://www.pharmaradar360.com/article/bd527c26e3a5daf8PharmaRadar360en2026-04-18T00:00:00.000ZCausal inference of glucocorticoid signaling in non-small cell lung cancer: integrating Mendelian randomization, single-cell transcriptomics, and imaging datahttps://www.pharmaradar360.com/article/97a1509a7893a936PharmaRadar360en2026-04-18T00:00:00.000ZA noninvasive urinary microRNA-based assay for early detection of lung cancer and its potential application to prognosis and recurrence monitoring: a case–control studyhttps://www.pharmaradar360.com/article/cc97635706088010PharmaRadar360en2026-04-18T00:00:00.000ZValidation of QuANTUM-derived tumor cell fraction for molecular testing in high-grade serous tubo-ovarian carcinomahttps://www.pharmaradar360.com/article/55d26467c658da5dPharmaRadar360en2026-04-18T00:00:00.000ZBeneficial bystander-enhanced cryptic splice rescue of cardiac-type Fabry GLA IVS4+919G>A by adenine base editing in patient fibroblastshttps://www.pharmaradar360.com/article/22d1bbd1077ada9bPharmaRadar360en2026-04-18T00:00:00.000ZMagnetic muon measurements and gene-therapy advances win US$3 million Breakthrough prizeshttps://www.pharmaradar360.com/article/3b381c66da1260fePharmaRadar360en2026-04-17T23:33:00.000ZAACR: FDA vet Pazdur bemoans state of agency, warns of political influence and ‘sense of anxiety’https://www.pharmaradar360.com/article/5a13a2c4d22764d3PharmaRadar360en2026-04-17T21:04:45.000ZPew Biomedical Scholars – Limited Submissionhttps://www.pharmaradar360.com/article/6c27b0b8e0af5c65PharmaRadar360en2026-04-17T21:03:48.000ZInnovación UC reemplaza la evaluación subjetiva del vino por datos medibleshttps://www.pharmaradar360.com/article/e6b126e68bc66b7ePharmaRadar360en2026-04-17T20:53:13.000ZIn hopeful sign for biotech, obesity treatment firm Kailera raises $625 million in upsized IPOhttps://www.pharmaradar360.com/article/eca3ec74a72c0f80PharmaRadar360en2026-04-17T20:51:24.000ZKailera nets $625M in one of biotech’s biggest-ever IPOshttps://www.pharmaradar360.com/article/e138125857acf074PharmaRadar360en2026-04-17T20:30:00.000ZUNFPA Funding and Kemp-Kasten: An Explainerhttps://www.pharmaradar360.com/article/ec777a0bc4db0133PharmaRadar360en2026-04-17T20:21:42.000ZTunneling Neurons in Adult Bird Brains Provide New Insights into Neurogenesishttps://www.pharmaradar360.com/article/df017f2bf95d1579PharmaRadar360en2026-04-17T20:00:00.000ZNotice of REDCap data security incidenthttps://www.pharmaradar360.com/article/9b393ddab24317faPharmaRadar360en2026-04-17T19:59:39.000ZExplore Carolina’s botanical history at the garden tourhttps://www.pharmaradar360.com/article/ab6f0ab116f7b43ePharmaRadar360en2026-04-17T19:54:40.000ZKelly Rhys-Jones - Chief People Officerhttps://www.pharmaradar360.com/article/1ed2296e0eed482ePharmaRadar360en2026-04-17T19:47:55.000ZTargeted Gene Delivery Calms Lung Inflammation in Respiratory Infection Mouse Modelshttps://www.pharmaradar360.com/article/59c0505b24b6c149PharmaRadar360en2026-04-17T19:36:15.000ZInside the insect collection at the University of Minnesotahttps://www.pharmaradar360.com/article/4dba60fb2aac761fPharmaRadar360en2026-04-17T19:35:42.000ZU of M researchers launch startup aiming to reduce AI energy consumptionhttps://www.pharmaradar360.com/article/46c01b0b9f9fb3b8PharmaRadar360en2026-04-17T19:34:48.000ZUniversity of Minnesota med school dean shares ‘innovation and vision’ on visit to St. Cloudhttps://www.pharmaradar360.com/article/e0770cd677e5db19PharmaRadar360en2026-04-17T19:31:35.000ZNext-generation clinical research: An integrated solution for pre-screeninghttps://www.pharmaradar360.com/article/f6236872dba2a5afPharmaRadar360en2026-04-17T19:29:00.000ZDiscovery and Characterization of a Potent and Selective Oral Inhibitor of STAT6 for the Treatment of Allergic Diseaseshttps://www.pharmaradar360.com/article/e67bad4f30796727PharmaRadar360en2026-04-17T19:22:12.000ZInSet® Interview with Dr. Veronica Diazhttps://www.pharmaradar360.com/article/95cad6bd54eb918cPharmaRadar360en2026-04-17T19:01:38.000ZZymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platformhttps://www.pharmaradar360.com/article/43283caaf0ec7f72PharmaRadar360en2026-04-17T18:29:55.000Z'Defer to breast cancer diagnosis and treatment experts': Imaging leaders rail against new ACP breast cancer screening recshttps://www.pharmaradar360.com/article/525c92782b5e4919PharmaRadar360en2026-04-17T18:29:00.000ZTwo Northeast Ohio changemakers triumph in competition to end cardiovascular diseasehttps://www.pharmaradar360.com/article/61c7b37be3a7c75fPharmaRadar360en2026-04-17T18:15:00.000ZProfessor Michael Laub and MIT alumni named 2025 AAAS Fellowshttps://www.pharmaradar360.com/article/bcb3511927a71027PharmaRadar360en2026-04-17T18:04:00.000ZQ&A: Understanding Pneumococcal Disease Burden and Vaccine Opportunitieshttps://www.pharmaradar360.com/article/993cf944321af3b1PharmaRadar360en2026-04-17T17:58:00.000ZLocal construction executive advances awareness, advocacy and heart health education in Browardhttps://www.pharmaradar360.com/article/cf8272767007f3a6PharmaRadar360en2026-04-17T17:47:48.000ZNew mammogram policy: Maryland to require BAC notifications with first law of its kindhttps://www.pharmaradar360.com/article/0470c9bfe2587856PharmaRadar360en2026-04-17T17:35:00.000ZUBC researchers aim to deliver earlier warnings on the toxic drug supplyhttps://www.pharmaradar360.com/article/aada987eba981d03PharmaRadar360en2026-04-17T17:31:00.000ZFounder and CEO raises awareness and funds to end women’s No. 1 health threathttps://www.pharmaradar360.com/article/621a8e54844efad0PharmaRadar360en2026-04-17T17:17:43.000ZNew CDC pick Schwartz is praised by public health proshttps://www.pharmaradar360.com/article/d5a21fa735264fcePharmaRadar360en2026-04-17T17:16:11.000ZFor What’s Next: Preparing Today’s Lab or Tomorrow’s Discoverieshttps://www.pharmaradar360.com/article/ea70114e186245dfPharmaRadar360en2026-04-17T17:07:11.000ZSK pharmteco Achieves SBTi Validation for 2040 Net-Zero Science-Based Targetshttps://www.pharmaradar360.com/article/32cf592412ebdfd6PharmaRadar360en2026-04-17T16:59:12.000ZFDA Approves Sotyktu From Bristol Myers Squibbhttps://www.pharmaradar360.com/article/83e929de77cf4b88PharmaRadar360en2026-04-17T16:58:12.000ZWhat Are the Recent Trends in Employer-Based Health Coverage?https://www.pharmaradar360.com/article/5e610ce54e3cf7c7PharmaRadar360en2026-04-17T16:49:25.000ZSPECIAL FEATURE - Bioavailability & Solubility: Experimental Techniques Combined With Computational Decision-Making Rapidly ID the Most Viable Enhancement Pathwayhttps://www.pharmaradar360.com/article/0f337f84ff934283PharmaRadar360en2026-04-17T16:47:51.000ZWhich Pregnancy Symptoms Require Urgent Care?https://www.pharmaradar360.com/article/e7450411df0a56dfPharmaRadar360en2026-04-17T16:40:11.000ZThe State of Multiomics & NGShttps://www.pharmaradar360.com/article/777fae8f4db6ecbcPharmaRadar360en2026-04-17T16:33:00.000ZNine Intermountain Health Hospitals Named to Nation’s 2026 100 Top Hospitals by Modern Healthcare and Premierhttps://www.pharmaradar360.com/article/c0351d9cdc64344bPharmaRadar360en2026-04-17T16:31:27.000Zcontextflow collaborates with VUNO and Mesalvo to advance cardiac arrest prediction solutionhttps://www.pharmaradar360.com/article/dbadf1c70368cb8ePharmaRadar360en2026-04-17T16:30:00.000ZDe-escalating Treatment in HER2-Positive Breast Cancer: Doing More With Lesshttps://www.pharmaradar360.com/article/65c209eca4ddc2d5PharmaRadar360en2026-04-17T16:29:00.000ZEPS-3903 Is a Potent and Selective Oral STAT6 Inhibitor That Blocks Th2 Inflammation in an Ovalbumin Asthma Mouse Modelhttps://www.pharmaradar360.com/article/9a35214c11b1325dPharmaRadar360en2026-04-17T16:20:00.000ZProposed DTW Cigar Lounge Puts Smoke‑Free Protections at Riskhttps://www.pharmaradar360.com/article/3be8f271c3e76be4PharmaRadar360en2026-04-17T16:06:25.000ZKailera IPO interview: CEO Renaud talks biotech market, China and obesity pipelinehttps://www.pharmaradar360.com/article/662ec5b393f8d2caPharmaRadar360en2026-04-17T16:00:00.000ZInside Pharma's Revenue Engine: The Gross-to-Net Reckoninghttps://www.pharmaradar360.com/article/cde4b7cf14e2d773PharmaRadar360en2026-04-17T16:00:00.000ZOptimizing Specialty Medication Access in Community Pharmacy: A Practical Workflow Approachhttps://www.pharmaradar360.com/article/accd7bc7c48ca675PharmaRadar360en2026-04-17T16:00:00.000ZNew nominee may need a charm at the CDChttps://www.pharmaradar360.com/article/c6b9f1494c47bde7PharmaRadar360en2026-04-17T15:45:00.000ZAffordability, transparency: A look at large employers' top healthcare concernshttps://www.pharmaradar360.com/article/9ac3e9fdc81a9ccdPharmaRadar360en2026-04-17T15:38:49.000Z#AACR26 preview: Revolution Medicines, the RAS bonanza and China ADC standoutshttps://www.pharmaradar360.com/article/0eca8fc837639a55PharmaRadar360en2026-04-17T15:32:00.000Z$1 Million gift will further research about congenital heart defectshttps://www.pharmaradar360.com/article/835860fceeead74cPharmaRadar360en2026-04-17T15:30:00.000ZFrom Burnout to Balance: How Walgreens' Hybrid Model Is Addressing the Pharmacyhttps://www.pharmaradar360.com/article/30190b5d487d03d5PharmaRadar360en2026-04-17T15:17:56.000ZOncology Pulse Points: ASCO WBC Growth Factors Guidelines Updatehttps://www.pharmaradar360.com/article/1b4b544da41a29e9PharmaRadar360en2026-04-17T15:16:47.000ZEli Lilly’s Oral Weight Loss Pill Prescribed Over 1,000 Times in First Days on Markethttps://www.pharmaradar360.com/article/e409826a1d76fd07PharmaRadar360en2026-04-17T15:10:29.000ZTrevi raises $150M; Spain and Boston set up biotech fundhttps://www.pharmaradar360.com/article/c4b9a5c00e283df2PharmaRadar360en2026-04-17T15:03:07.000ZIEC 62304 software safety classes: what they are and how to apply themhttps://www.pharmaradar360.com/article/9f9a730f183dd574PharmaRadar360en2026-04-17T14:35:40.000ZEmergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibilityhttps://www.pharmaradar360.com/article/db51fb73338150e1PharmaRadar360en2026-04-17T14:30:13.000ZKailera makes history with record-breaking $625m IPOhttps://www.pharmaradar360.com/article/4fbb5f2158882d77PharmaRadar360en2026-04-17T14:15:59.000ZPresident Trump Nominates Dr. Erica Schwarts for CDC Leadership Rolehttps://www.pharmaradar360.com/article/61608da20ac74394PharmaRadar360en2026-04-17T14:11:25.000ZRoche to launch global study of Elevidys following EU rejection